No Data
Changchun BCHT Biotechnology (SHSE:688276) Has A Pretty Healthy Balance Sheet
Baige Biotechnology (688276.SH) shareholder Wei Xueling's shareholding has decreased to 5%.
Baike Biotechnology (688276.SH) announced that shareholder Wei Xuening's shareholding ratio decreased from 8.7225%...
Public Companies Who Hold 41% of Changchun BCHT Biotechnology Co. (SHSE:688276) Gained 4.1%, Insiders Profited as Well
Changchun Baike Biotechnology Co., Ltd. report for the third quarter of 2024
Sales of the herpes zoster vaccine declined, dragging down Bacillus's third-quarter revenue by over 40%.
① Due to the reduction in sales of attenuated live herpes zoster vaccine, Baike Biotechnology achieved a year-on-year decrease in revenue of 40.37% in the third quarter, with a year-on-year decrease in net income attributable to the parent company of 51.41%; ② Currently, in addition to GSK's herpes zoster vaccine competing with Baike Biotechnology in the domestic market, there are over 10 companies developing similar products, Baike Biotechnology faces multiple potential competitors.
Baike Biological (688276.SH) released its performance for the first three quarters, with a net income of 0.244 billion yuan, a year-on-year decrease of 26.19%.
Baike Biological (688276.SH) released the report for the first three quarters of 2024, during the reporting period the company achieved revenue...
Investors Still Waiting For A Pull Back In Changchun BCHT Biotechnology Co. (SHSE:688276)No Data
No Data
